Carotid surgery in private practice: what kind of change in the last 15 years?

BACKGROUND: This retrospective study analyzes and compares the results of patients undergoing carotid endarterectomy (CE) for atherosclerotic stenosis obtained by 2 surgeons during two 5-year periods. Group 1 (G1) represents the first period (January 1994-December 1998) and group 2 (G2) represents the second period (January 2006-December 2010). Our objective was to answer the 2 following questions: (1) Has the population changed between these 2 periods with regard to age, risk factors, and symptoms? (2) Have the techniques we used in G2--local anesthesia and eversion technique--improved the results? METHODS: G1 included 682 CE procedures on 610 patients and G2 included 629 procedures on 592 patients. The following factors were analyzed in G1 and G2: distribution of age and sex, the main risk factors (diabetes and cardiovascular risk), symptomatology, the degree of stenosis, the preoperative computed tomography (CT) data, the type of anesthesia (general or local), the use of an intraoperative shunt, surgical techniques, postoperative patency, cardiac complications, central and peripheral neurologic complications, and reoperations. In conformity with the North American Symptomatic Carotid Endarterectomy Trial classifications, stenosis of >70% was included in this survey. Loops, tumors, aneurysms, and restenosis were excluded. Heparin (300 U.I./kg) was administered. Shunt placing was selective. The 3 most common techniques used were eversion, longitudinal CE with patch angioplasty, and CE with direct closure. Postoperative patency was controlled by intravenous digital angiography or duplex ultrasonography. Follow-up occurred until postoperative day 30. RESULTS: Compared with G1, the incidence of arterial hypertension, diabetes, and coronary atherosclerosis treated by angioplasty increased significantly in G2; local anesthesia replaced general anesthesia in G2, and fewer intraoperative shunts were used (P = 0.034). The technique of direct closure of the arteriotomy was no longer used. In contrast to G1, in G2 no postoperative carotid thromboses (P = 1.8) and no lethal strokes (P = 5.44) were observed. The incidence of major adverse cardiovascular events on postoperative day 30 was 1.7% in G1 compared with 0.79% in G2. The combined mortality and morbidity rate--including reoperations and peripheral neurologic deficits--was 3.95% in G1 compared with 3.81% in G2. CONCLUSION: Despite a major increase in risk factors, the combined use of local anesthesia and eversion technique, when technically feasible, improved our results in G2.

Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model.

INTRODUCTION: The aim of this prospective, randomized, controlled, double-blind study was to evaluate the effects of tiludronate (TLN), a bisphosphonate, on structural, biochemical and molecular changes and function in an experimental dog model of osteoarthritis (OA). METHODS: Baseline values were established the week preceding surgical transection of the right cranial/anterior cruciate ligament, with eight dogs serving as OA placebo controls and eight others receiving four TLN injections (2 mg/kg subcutaneously) at two-week intervals starting the day of surgery for eight weeks. At baseline, Week 4 and Week 8, the functional outcome was evaluated using kinetic gait analysis, telemetered locomotor actimetry and video-automated behaviour capture. Pain impairment was assessed using a composite numerical rating scale (NRS), a visual analog scale, and electrodermal activity (EDA). At necropsy (Week 8), macroscopic and histomorphological analyses of synovium, cartilage and subchondral bone of the femoral condyles and tibial plateaus were assessed. Immunohistochemistry of cartilage (matrix metalloproteinase (MMP)-1, MMP-13, and a disintegrin and metalloproteinase domain with thrombospondin motifs (ADAMTS5)) and subchondral bone (cathepsin K) was performed. Synovial fluid was analyzed for inflammatory (PGE(2) and nitrite/nitrate levels) biomarkers. Statistical analyses (mixed and generalized linear models) were performed with an α-threshold of 0.05. RESULTS: A better functional outcome was observed in TLN dogs than OA placebo controls. Hence, TLN dogs had lower gait disability (P = 0.04 at Week 8) and NRS score (P = 0.03, group effect), and demonstrated behaviours of painless condition with the video-capture (P < 0.04). Dogs treated with TLN demonstrated a trend toward improved actimetry and less pain according to EDA. Macroscopically, both groups had similar level of morphometric lesions, TLN-treated dogs having less joint effusion (P = 0.01), reduced synovial fluid levels of PGE(2) (P = 0.02), nitrites/nitrates (P = 0.01), lower synovitis score (P < 0.01) and a greater subchondral bone surface (P < 0.01). Immunohistochemical staining revealed lower levels in TLN-treated dogs of MMP-13 (P = 0.02), ADAMTS5 (P = 0.02) in cartilage and cathepsin K (P = 0.02) in subchondral bone. CONCLUSION: Tiludronate treatment demonstrated a positive effect on gait disability and joint symptoms. This is likely related to the positive influence of the treatment at improving some OA structural changes and reducing the synthesis of catabolic and inflammatory mediators.

Treatment with tiludronic acid helps reduce the development of experimental osteoarthritis lesions in dogs with anterior cruciate ligament transection followed by reconstructive surgery: a 1-year study with quantitative magnetic resonance imaging.

OBJECTIVE: to investigate over a 1-year period in dogs that underwent extracapsular stabilization surgery (ECS) following anterior cruciate ligament (ACL) transection: whether reconstructive surgery could prevent osteoarthritis (OA) progression and whether treatment with the bisphosphonate tiludronic acid (TA) could improve the chronic evolution of OA structural changes. METHODS: ACL transection was performed on dogs on Day 0 and ECS on Day 28. Dogs were randomly divided into 2 groups: 15 received placebo and 16 were treated with TA (2 mg/kg subcutaneous injection) on Days 14, 28, 56, and 84. Magnetic resonance images were acquired on Days -10, 26, 91, 210, and 357, and cartilage volume was quantified. At sacrifice (Day 364), cartilage from femoral condyles and tibial plateaus was macroscopically and histologically evaluated. Expression levels of MMP-1, -3, -13, ADAMTS-4, -5, BMP-2, FGF-2, IGF-1, TGF-ß1, collagen type II, and aggrecan were determined using real-time RT-PCR. RESULTS: the loss of cartilage volume observed after ACL transection stabilized following ECS. Thereafter, a gradual gain occurred, with the cartilage volume loss on the tibial plateaus reduced at Day 91 (p < 0.02) and Day 210 (p < 0.001) in the TA-treated dogs. At sacrifice, TA-treated dogs presented a reduction in the severity of macroscopic (p = 0.03 for plateaus) and histologic (p = 0.07 for plateaus) cartilage lesions, had a better preserved collagen network, and showed decreased MMP-13 (p = 0.04), MMP-1 and MMP-3 levels. CONCLUSION: our findings indicate that in dogs with ACL transection, ECS greatly prevents development of cartilage volume loss. Treatment with TA provided an additional benefit of reducing the development of OA lesions.

Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column.

OBJECTIVE: To evaluate the efficacy of tiludronate for the treatment of horses with signs of pain associated with lesions of the thoracolumbar vertebral column. ANIMALS: 29 horses with clinical manifestations of pain associated with lesions of the thoracolumbar vertebral column and abnormal radiographic findings indicative of osteoarthritis of the articular processes-synovial intervertebral joints. PROCEDURES: Horses were initially examined in accordance with a standardized protocol, which included radiographic, ultrasonographic, and scintigraphic examinations. Fifteen horses were randomly assigned to receive tiludronate (1 mg/kg, IV, as a slow-rate infusion), and 14 horses received a control substance (day 0). Horses were monitored for the subsequent 120 days. Clinical evaluations were performed on days 60 and 120. Horses that had no evidence of clinical improvement on day 60 were administered tiludronate. Statistical analyses were performed to compare efficacy at day 60, improvement of dorsal flexibility at day 120, and dorsal flexibility before and 60 days after administration of tiludronate. RESULTS: Horses treated with tiludronate had significant improvement in dorsal flexibility between days 0 and 60, compared with control horses. Clinical improvement in dorsal flexibility was still evident at day 120. The percentage of positive responses was higher in the tiludronate group at 60 days. CONCLUSIONS AND CLINICAL RELEVANCE: Tiludronate had efficacy in the treatment of horses with signs of pain induced by osteoarticular lesions of the thoracolumbar vertebral column, causing a significant improvement in dorsal flexibility. Tiludronate may offer a treatment option for the management of horses with intervertebral lesions and the associated pain.